circRNA basic information
circBase ID: hsa_circ_0003855
Name: hsa_circ_DUSP16
Synonym: circDUSP16
Host Gene: DUSP16
Genomic location(hg19): chr12:12672795-12674397:-
Genomic location(hg38): chr12:12519861-12521463:-
Subcellular localization: cytoplasm
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0005494
MONDO name: triple-negative breast carcinoma
Disease details: triple-negative breast cancer
Disease DO ID:
 0060081
Disease MeSH ID:
 D064726
Disease NCIt ID:
 C71732
Disease ICD11 ID:
 -
Disease OMIM ID:
 -
Species: Human
Species details: Homo sapiens
Tissue specimen:

breast cancer tissues; adjacent normal breast tissues; plasma exosomes; xenograft tumors
Cell lines:

MCF-10A; MCF-7; BT-474; SKBR-3; MDA-MB-231; MDA-MB-468; MDA-MB-436
In vivo animal model:

cell line-derived xenograft
circRNA-disease information
Expression pattern:
UP
Associated gene: TFDP2, Cyclin D1, CDK4, Ki67
Associated microRNA: miR-1224-3p
Biological function: Promotes TNBC cell proliferation, migration, invasion, and xenograft tumor growth; circDUSP16 knockdown inhibits tumor growth; THP downregulates circDUSP16 and suppresses TNBC malignant phenotypes.
Molecular mechanism: circDUSP16 acts as a cytoplasmic ceRNA that sponges miR-1224-3p, thereby upregulating TFDP2 mRNA expression and promoting TNBC progression; pirarubicin may inhibit TNBC partly by downregulating circDUSP16 and the circDUSP16/miR-1224-3p/TFDP2 pathway.
Biological pathway or process:

ceRNA regulation (promotes); proliferation (promotes); migration (promotes); invasion (promotes); cell cycle (promotes); drug resistance (other); metastasis (promotes)
Detected method:
Q
S
M
Validation methods:

Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; circRNA-seq; Microarray; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RNA Pull-Down; Transfection; CCK8; Western Blot; Wound Healing Assay; Transwell Assay; In Vivo Animal Model; IHC (Immunohistochemistry); IF (Immunofluorescence); Survival Analysis; Bioinformatics Analysis
Clinical significance:

circDUSP16 may serve as a promising biomarker and potential therapeutic target for TNBC; high circDUSP16 expression in plasma exosomes predicted poor overall survival and was associated with lymphatic metastasis; tissue circDUSP16 expression was associated with tumor size.
Description:

circDUSP16 (hsa_circ_0003855), derived from DUSP16, is upregulated in TNBC tissues, cells, and plasma exosomes and predicts poor overall survival when highly expressed in plasma exosomes. It promotes TNBC proliferation, migration, invasion, and xenograft growth mainly through a cytoplasmic ceRNA mechanism involving miR-1224-3p and TFDP2. Pirarubicin downregulates circDUSP16, suggesting that the circDUSP16/miR-1224-3p/TFDP2 axis may contribute to the therapeutic response in TNBC.
Confidence score:

0.863
Other information
Title:

CircDUSP16 mediates the effect of triple-negative breast cancer in pirarubicin via the miR-1224-3p/TFDP2 axis.

Journal: Biochemical pharmacology
Published: 2025
PubMed ID: 39710273
Study type:

combined biological and clinical study
Data availability: I have shared the link to my data
Code availability: -